Stonvex
Stonvex
StonvexIntuitive Surgical stock has declined 30% from early 2025 peaks but trades 30%+ below Wall Street's average $570 price target. The da Vinci surgical robotics platform demonstrates robust demand with 12% YoY growth in installed systems and 17% growth in procedures performed, with 75% of revenue derived from recurring instruments, accessories, and services.
Intuitive Surgical stock has fallen 30% from early 2025 highs but Wall Street analysts maintain an average price target of $570, suggesting 30%+ upside potential. The surgical robotics leader's da Vinci system shows strong demand with 12% year-over-year growth in installed systems and 17% growth in surgeries performed. While the stock trades at a lofty 51x P/E ratio, analysts believe the company's recurring revenue from instruments, accessories, and services (75% of revenue) and long-term market opportunity justify recovery, supported by historical precedent of similar drawdowns followed by strong recoveries.
Summary and sentiment are generated by AI for educational purposes. Always verify with the original source before making investment decisions.
Risk warning
Investing in equities carries significant risk, including the potential loss of your entire investment. Volatility, liquidity, geopolitical, and currency risks can all materially affect outcomes. Past performance does not guarantee future results. Nothing on Stonvex is investment advice, a recommendation, or a solicitation to buy or sell any security. Stonvex is not a registered investment advisor (RIA), broker-dealer, or financial planner. You should consult a licensed advisor before making investment decisions and only invest capital you can afford to lose.
© 2026 Stonvex. All rights reserved.
Service not available to residents of: Belarus, China, Cuba, France, Germany, India, Iran, Japan, North Korea, Russia, South Korea, Sudan, Syria. See Terms. You must be 18 years or older to use this service.